Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ASLAN Strikes First Licensing Out Deal For Lead Project

This article was originally published in PharmAsia News

Executive Summary

Hyundai Pharm, a mid-sized South Korean pharma firm, is to license in local rights to Singapore venture ASLAN’s lead development molecule varlitinib, a novel small molecule pan-HER inhibitor for cholangiocarcinoma, in a move to boost its oncology pipeline.



Related Companies